| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2017-10-03 |
| タイトル |
|
|
タイトル |
Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.24517/00014078 |
|
ID登録タイプ |
JaLC |
| 著者 |
Terashima, Takeshi
Yamashita, Tatsuya
Arai, Kuniaki
Sunagozaka, Hajime
Kitahara, Masaaki
Nakagawa, Hidetoshi
Kagaya, Takashi
Mizukoshi, Eishiro
Honda, Masao
Kaneko, Shuichi
|
| 著者別表示 |
寺島, 健志
山下, 竜也
荒井, 邦明
砂子坂, 肇
北原, 征明
加賀谷, 尚史
水腰, 英四郎
本多, 政夫
金子, 周一
|
| 提供者所属 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
金沢大学先進予防医学研究センター / 金沢大学医薬保健研究域医学系 |
| 書誌情報 |
Hepatology Research
巻 44,
号 12,
p. 1179-1185,
発行日 2014-11-01
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1386-6346 |
| NCID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA11140867 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1111/hepr.12266 |
| 出版者 |
|
|
出版者 |
Blackwell Publishing / 日本肝臓学会 Japan Society of Hepatology |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Aim: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC). However, although there is no proven therapeutic procedure following the termination of sorafenib, hepatic arterial infusion chemotherapy (HAIC) may be a treatment option in advanced HCC. The aim of this study was to evaluate feasibility and efficacy of HAIC for patients with advanced HCC as subsequent therapy. Methods: We retrospectively evaluated 27 consecutive patients with advanced HCC who were treated with HAIC following sorafenib between June 2009 and December 2012 at our hospital. Cisplatin (20 mg/m2 per day) was administered via the hepatic artery for 10 min, prior to the continuous administration of 5-fluorouracil (330 mg/m2 per day) over 24 h from days 1-5 and 8-12 and the s.c. administration of pegylated interferon α-2b (1 μg/kg) on days 1, 8, 15, and 22. A treatment cycle consisted of 28 days of drug administration followed by 14 days of rest. Results: The toxicity profile showed that hematological toxicities were common, and grade 3/4 neutropenia and thrombocytopenia were observed (51.9% and 48.1%, respectively). Five patients (18.5%) experienced device-related complications. No unexpected adverse reactions and no treatmentrelated deaths were observed. Partial response was obtained in eight patients (29.6%), and stable disease was noted in nine patients (33.3%). Median progression-free survival and median survival time from initiation of HAIC were 4.0 and 7.6 months, respectively. Conclusions: Because HAIC was well tolerated and exhibited moderate antitumor activity, it is a potentially useful treatment procedure in patients with advanced HCC even after failure of sorafenib. |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
ME-PR-KANEKO-S-1179.pdf (319.9 kB)
.png)
